Amano Toshiyasu, Earle Carolyn, Imao Tetsuya, Matsumoto Yuki, Kishikage Takahiro
a Department of Urology , Nagano Red Cross Hospital , Nagano , Japan.
b Subiaco Sexology , Subiaco , Australia.
Aging Male. 2018 Mar;21(1):77-82. doi: 10.1080/13685538.2017.1367922. Epub 2017 Aug 22.
Tadalafil is a promising phosphodiesterase (PDE) 5 inhibitor prescribed for erectile dysfunction (ED). Daily low dose (5 mg) of tadalafil has also been used for the treatment of male lower urinary tract symptoms (LUTS) associated with benign prostate hyperplasia (BPH). PDE5 inhibitors induce relaxation of smooth muscle cells in the urethra, prostate, bladder neck, and blood vessels. The aim of this study was to investigate the efficacy of tadalafil on vessels endothelial function, in patients with male LUTS symptoms associated with BPH.
The Institutional Review Board (IRB) approved this clinical study and informed consents had been obtained from 81 BPH patients. The following male LUTS parameters: international prostate symptom score (IPSS), overactive bladder symptom score (OABSS), voiding volume, max and mean voiding flow on voiding flowmetry examination and post-voiding residual urine (RU) were compared at 0, 1, 3, 6, and 12 months after a daily dose of 5 mg tadalafil. In addition, erectile function was evaluated by the sexual health inventory for men (SHIM) score and vessels endothelial function and peripheral neuropathy were assessed by the brachial-ankle pulse wave velocity (baPWV), ankle brachial index (ABI), and vibration perception threshold (VPT) at 0, 3, 6, and 12 months after treatment.
The mean age of 81 patients was 66.4 ± 11.4 years old. Their prostate size was 30.2 ± 22.1 ml. Male LUTS parameters including IPSS, OABSS, and RU showed significant improvement from 1 to 12 months after tadalafil administration. Max and mean voiding flow was significantly increased at 6 months after tadalafil treatment. The SHIM score showed significant improvement after 3 months. Whilst, the results of baPWV also showed significant improvement from 3 to 12 months. ABI was also significantly improved at 6 months. However, there was no change in the VPT at any time point.
Tadalafil is effective for both male LUTS and ED. It is also shown that tadalafil improves baPWV, which we can conclude that higher vessels elasticity has been obtained. This major finding of this study shows that tadalafil has the potency to improve vessels endothelial dysfunction in patients with BPH.
他达拉非是一种有前景的磷酸二酯酶(PDE)5抑制剂,用于治疗勃起功能障碍(ED)。每日低剂量(5毫克)的他达拉非也已用于治疗与良性前列腺增生(BPH)相关的男性下尿路症状(LUTS)。PDE5抑制剂可诱导尿道、前列腺、膀胱颈和血管中的平滑肌细胞松弛。本研究的目的是调查他达拉非对伴有BPH的男性LUTS症状患者血管内皮功能的疗效。
机构审查委员会(IRB)批准了这项临床研究,并获得了81例BPH患者的知情同意书。比较了以下男性LUTS参数:国际前列腺症状评分(IPSS)、膀胱过度活动症症状评分(OABSS)、排尿量、排尿流量检查时的最大和平均排尿流量以及残余尿量(RU),这些参数在每日服用5毫克他达拉非后的0、1、3、6和12个月时进行比较。此外,通过男性性健康量表(SHIM)评分评估勃起功能,并在治疗后的0、3、6和12个月通过臂踝脉搏波速度(baPWV)、踝臂指数(ABI)和振动感觉阈值(VPT)评估血管内皮功能和周围神经病变。
81例患者的平均年龄为66.4±11.4岁。他们的前列腺体积为30.2±22.1毫升。包括IPSS、OABSS和RU在内的男性LUTS参数在服用他达拉非后的1至12个月显示出显著改善。他达拉非治疗6个月后,最大和平均排尿流量显著增加。SHIM评分在3个月后显示出显著改善。同时,baPWV的结果在3至12个月也显示出显著改善。ABI在6个月时也显著改善。然而,在任何时间点VPT均无变化。
他达拉非对男性LUTS和ED均有效。还表明他达拉非可改善baPWV,由此我们可以得出已获得更高血管弹性的结论。本研究的这一主要发现表明,他达拉非有改善BPH患者血管内皮功能障碍的潜力。